Published in Lancet Oncol on December 11, 2014
Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis. Ann Oncol (2015) 2.17
Low-Fat Dietary Pattern and Breast Cancer Mortality in the Women's Health Initiative Randomized Controlled Trial. J Clin Oncol (2017) 1.37
Can the breast screening appointment be used to provide risk assessment and prevention advice? Breast Cancer Res (2015) 1.01
Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers. EBioMedicine (2015) 0.93
Contribution of the Unified Health Care System to mammography screening in Brazil, 2013. Radiol Bras (2016) 0.90
Molecular cancer prevention: Current status and future directions. CA Cancer J Clin (2015) 0.86
Barriers and Facilitators to Patient-Provider Communication When Discussing Breast Cancer Risk to Aid in the Development of Decision Support Tools. AMIA Annu Symp Proc (2015) 0.85
Chemoprevention for Breast Cancer. Ann Surg Oncol (2015) 0.83
Anastrozole in Pulmonary Arterial Hypertension (AIPH): A Randomized, Double-Blind Placebo-Controlled Trial. Am J Respir Crit Care Med (2016) 0.82
Cancer Prevention: Obstacles, Challenges and the Road Ahead. J Natl Cancer Inst (2015) 0.82
IBIS-I tamoxifen update: maturity brings questions. Lancet Oncol (2014) 0.80
Impact of preventive therapy on the risk of breast cancer among women with benign breast disease. Breast (2015) 0.79
Adipokines and Vascular Endothelial Growth Factor in Normal Human Breast Tissue in Vivo - Correlations and Attenuation by Dietary Flaxseed. J Mammary Gland Biol Neoplasia (2016) 0.78
Ongoing data from the breast cancer prevention trials: opportunity for breast cancer risk reduction. BMC Med (2015) 0.78
Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors. Cancer (2015) 0.77
Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake. Ecancermedicalscience (2015) 0.77
Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study. Breast Cancer Res (2016) 0.77
Breast cancer: tamoxifen - offering a long-term prevention option. Nat Rev Clin Oncol (2015) 0.76
Physician and Patient Barriers to Breast Cancer Preventive Therapy. Curr Breast Cancer Rep (2016) 0.75
Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials. Breast Cancer Res Treat (2016) 0.75
Primary chemoprevention of breast cancer: Are the adverse effects too burdensome? CMAJ (2015) 0.75
Report from the 37th san antonio breast cancer symposium, 9-13th december 2014, Texas, USA. Ecancermedicalscience (2015) 0.75
Mammographic density: a potential monitoring biomarker for adjuvant and preventative breast cancer endocrine therapies. Oncotarget (2016) 0.75
Breast Cancer Profile among Patients with a History of Chemoprevention. Int J Breast Cancer (2016) 0.75
Tamoxifen use and acute pancreatitis: A population-based cohort study. PLoS One (2017) 0.75
Tamoxifen reduces breast cancer rate in at-risk healthy women by nearly a third, finds study. BMJ (2014) 0.75
Statistical controversies in clinical research: long-term follow-up of clinical trials in cancer. Ann Oncol (2015) 0.75
Chemoprevention of cancer: current evidence and future prospects. F1000Res (2015) 0.75
The BMC Medicine breast cancer collection: an illustration of contemporary research and clinical care. BMC Med (2015) 0.75
Relationship of Predicted Risk of Developing Invasive Breast Cancer, as Assessed with Three Models, and Breast Cancer Mortality among Breast Cancer Patients. PLoS One (2016) 0.75
Decision making for breast cancer prevention among women at elevated risk. Breast Cancer Res (2017) 0.75
ACP Journal Club. Tamoxifen for 5 years reduced 16-year risk for breast cancer in women at increased risk. Ann Intern Med (2015) 0.75
How do Women at Increased Breast Cancer Risk Perceive and Decide Between Risks of Cancer and Risk-Reducing Treatments? A Synthesis of Qualitative Research. Psychooncology (2016) 0.75
How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention? NPJ Breast Cancer (2017) 0.75
Endometrial cancer gene panels: clinical diagnostic vs research germline DNA testing. Mod Pathol (2017) 0.75
Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials. J Clin Oncol (2016) 0.75
Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review. Hered Cancer Clin Pract (2017) 0.75
Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment. Breast Cancer Res Treat (2017) 0.75
Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma In Situ. Cancer Prev Res (Phila) (2017) 0.75
Expression and prognostic value of HER-2/neu in primary breast cancer with sentinel lymph node metastasis. Biosci Rep (2017) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst (1998) 22.10
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet (2011) 10.62
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst (2005) 7.70
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet (2002) 6.02
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet (1998) 5.35
Overview of the main outcomes in breast-cancer prevention trials. Lancet (2003) 4.31
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet (2013) 4.20
Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst (2007) 4.11
Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet (1998) 3.83
Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst (2007) 3.39
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet (2013) 3.31
Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst (2003) 3.20
Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst (2007) 1.97
Tamoxifen and contralateral breast cancer. Lancet (1985) 1.53
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet (2013) 4.20
Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. Lancet Oncol (2014) 1.55